GlaxoSmithKline Plc has announced the expansion of a collaboration with Amicus Therapeutics Inc aimed at developing and commercialising a new treatment for Fabry disease. Under the deal GSK will raise its stake in Amicus to 19.9%. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
